Celltrion has filed two additional petitions for inter partes review of Genentech patents related to trastuzumab: IPR2017-01139, challenging U.S. Patent 6,627,196, and IPR2017-01140, challenging U.S. Patent 7,371,379. According to the Petitions, the patents are drawn to methods for treating cancer by administering trastuzumab and a chemotherapeutic agent. Trastuzumab is sold by Genentech under the trade-name Herceptin®.
Celltrion has recently filed three petitions for review of other Genentech patents related to trastuzumab, as we previously reported.
These petitions and other significant documents related to IPRs on biologic patents are collected on our IPR tracker page.